T2DM is the one form prevails the most of the disease, accounting for nearly 90% of all cases worldwide. Metformin monotherapy is in high recommendation as first-line pharmacotherapy and higher number of options for second-line therapy has made a raise of uncertain situations in relation to optimal treatment pathway, especially selecting between DPP4i and sulfonylurea. This systematic review aims to make an overview of cost – effectiveness of vildagliptin and sulfonylurea combined with metformin in the second-line pharmacotherapy of T2DM. A review cycle was done by utilizing the sources of the data from Medline, Cochrane, Embase and Science direct with enough key word, abstract, published in English and full text published between January 2000 and November 2017 to identify health economic examinations that calculated the cost – effectiveness of vildagliptin (DDP4i) compared with sulfonylurea (SU) in a combination with metformin in the treatment of T2DM. The articles had critical ap

Type 2 diabetes mellitus, cost-effectiveness, metformin, vildagliptin, sulfonylurea.

This study demonstrated that Vildagliptin inhibitor when combined with metformin appeared as a treatment option that had effectiveness of cost in comparison to sulfonylurea for individuals with T2DM having a control of inadequacy on metformin mono-therapy. Finally, the study concluded that Vildagliptin combined with metformin is a more impactful treatment, but with a considerable cost.

Thuy, N.T.T., Linh, P.T.T., Ai, N.C., Trung, N.T. & Quan, N.M. (2019). Cost–Effectiveness Analysis of Vildagliptin versus Sulfonylurea Associated with Metformin in the Second-Line Pharmacotherapy of Type 2 Diabetes Mellitus: A Systematic Review. Biolog